212 related articles for article (PubMed ID: 35666055)
41. Evolution of patients with chronic hepatitis C infection with advanced fibrosis or cirrhosis cured with direct-acting antivirals. Long-term follow-up.
Badia Aranda E; Fernández Marcos C; Puebla Maestu A; Gozalo Marín V; Vinuesa Campo R; Calvo Simal S; Gómez Camarero J
Gastroenterol Hepatol; 2022 Dec; 45(10):767-779. PubMed ID: 35189262
[TBL] [Abstract][Full Text] [Related]
42. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
[TBL] [Abstract][Full Text] [Related]
43. HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
Steininger K; Boyd A; Dupke S; Krznaric I; Carganico A; Munteanu M; Neifer S; Schuetze M; Obermeier M; Arasteh K; Baumgarten A; Ingiliz P
J Viral Hepat; 2017 Oct; 24(10):832-839. PubMed ID: 28439936
[TBL] [Abstract][Full Text] [Related]
44. Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens.
Attia D; Deterding K; Cornberg J; Gebel MJ; Cornberg M; Manns MP; Wedemeyer H; Potthoff A
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):67-74. PubMed ID: 30239347
[TBL] [Abstract][Full Text] [Related]
45. Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C.
Benhammou JN; Moon AM; Pisegna JR; Su F; Vutien P; Moylan CA; Ioannou GN
Dig Dis Sci; 2021 Jul; 66(7):2394-2406. PubMed ID: 32654086
[TBL] [Abstract][Full Text] [Related]
46. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis.
Mecci AJ; Kemos P; Leen C; Lawson A; Richardson P; Khakoo SI; Agarwal K; Mutimer D; Rosenberg WM; Foster GR; Irving WL;
Aliment Pharmacol Ther; 2019 Jul; 50(2):204-214. PubMed ID: 31149748
[TBL] [Abstract][Full Text] [Related]
47. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR.
Nakagawa M; Asahina Y; Kakinuma S; Okamoto R
J Gastroenterol; 2023 Apr; 58(4):299-310. PubMed ID: 36585501
[TBL] [Abstract][Full Text] [Related]
48. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.
Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C
Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508
[TBL] [Abstract][Full Text] [Related]
49. Viral eradication by direct-acting antivirals does not decrease the serum myostatin level in patients infected with hepatitis C virus.
Endo K; Sato T; Yoshida Y; Kakisaka K; Miyasaka A; Takikawa Y
Nutrition; 2022 Sep; 101():111699. PubMed ID: 35700590
[TBL] [Abstract][Full Text] [Related]
50. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
51. Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals.
Lin CP; Liang PC; Huang CI; Yeh ML; Hsu PY; Hsu CT; Wei YJ; Liu TW; Hsieh MY; Hou NJ; Jang TY; Lin YH; Wang CW; Lin ZY; Chen SC; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
PLoS One; 2021; 16(2):e0245479. PubMed ID: 33539408
[TBL] [Abstract][Full Text] [Related]
52. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
Jacobson IM; Lim JK; Fried MW
Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
[TBL] [Abstract][Full Text] [Related]
53. A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Silva IPL; Batista AD; Lopes EP; Filgueira NA; Carvalho BT; Santos JC; Medeiros TB; Melo CRL; Lima MS; Lima K; Lacerda C; Lacerda HR
Rev Inst Med Trop Sao Paulo; 2021; 63():e6. PubMed ID: 33533809
[TBL] [Abstract][Full Text] [Related]
54. Follow-up of patients with chronic hepatitis C and a sustained viral response.
Serfaty L
Liver Int; 2016 Jan; 36 Suppl 1():67-71. PubMed ID: 26725900
[TBL] [Abstract][Full Text] [Related]
55. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
56. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
57. Prevalence and predictors of abnormal alanine aminotransferase in patients with HCV who have achieved SVR.
Chadha N; Turner A; Sterling RK
J Viral Hepat; 2023 Jan; 30(1):73-78. PubMed ID: 36301045
[TBL] [Abstract][Full Text] [Related]
58. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality.
Wang Y; Rao H; Chi X; Li B; Liu H; Wu L; Zhang H; Liu S; Zhou G; Li N; Niu J; Wei L; Zhao J
EBioMedicine; 2019 Aug; 46():227-235. PubMed ID: 31345785
[TBL] [Abstract][Full Text] [Related]
59. Analysis of hepatic stiffness after viral eradication in a population with chronic hepatitis C treated with DAAs.
Sangineto M; Luglio CV; Mastrofilippo T; Zingaro MT; Berardi E; Antonica G; Sabbà C; Napoli N
Med Clin (Barc); 2021 Apr; 156(7):317-323. PubMed ID: 32788043
[TBL] [Abstract][Full Text] [Related]
60. Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus.
Tamaki N; Kurosaki M; Yasui Y; Mori N; Tsuji K; Hasebe C; Joko K; Akahane T; Furuta K; Kobashi H; Kimura H; Yagisawa H; Marusawa H; Kondo M; Kojima Y; Yoshida H; Uchida Y; Loomba R; Izumi N
Clin Infect Dis; 2021 Nov; 73(9):e3349-e3354. PubMed ID: 33544129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
